Our Mission

Our Mission is to improve the lives of patients suffering from difficult to treat cancers by developing a broad spectrum immunomodulator that primes and boosts the immune response and enhance the performance of cancer treatment.

About Us

Immodulon is a late-stage clinical biotechnology company developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. Immodulon is developing IMM-101, a heat-killed Mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumours including those considered to be immunologically “cold,” such as pancreatic cancer.

Latest from Immodulon